Oncostellae is a biotech startup developing small-molecule drugs with innovative scaffolds (NCEs) that modulate clinically
validated therapeutic targets in oncology and inflammatory/autoimmune diseases.
The company was founded in 2013 by a team of medicinal chemists and pharmacologists with a common track record in drug discovery who bring together the experience and network of
collaborators to develop clinical candidates from their conception until Phase I/II. Further development and commercialization rights will be licensed to consolidated pharmaceutical
In 2014 Guido Kurz, a seasoned research manager with international trajectory in various pharmaceutical and biotech companies (including Pharmacia Corp. and Oryzon Genomics), joined
Oncostellae as CEO of the company.